Skip to main content

Table 1 Baseline characteristics

From: Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial

  Placebo (N = 50) NEPA200/0.5(N = 49) NEPA600/1.5(N = 49) Moxifloxacin (N = 49)
Age, years     
 Mean (SD) 34.7 (7.12) 33.6 (6.86) 32.8 (8.36) 34.7 (7.98)
 Min–max 19–45 21–44 19–45 19–45
Gender, n (%)     
 Male 26 (52) 27 (55) 27 (55) 26 (53)
 Female 24 (48) 22 (45) 22 (45) 23 (47)
BMI, kg/m2     
 Mean (SD) 24.45 (2.486) 24.27 (2.608) 24.51 (2.516) 24.89 (2.674)
 Min–max 19.0–28.9 19.2–28.5 19.4–28.9 19.4–29.0
  1. BMI, body mass index; SD, standard deviation.
  2. NEPA200/0.5: 200 mg netupitant (50 mg + 150 mg) + 0.50 mg palonosetron (1 × 0.50 mg).
  3. NEPA600/1.5: 600 mg netupitant (4 × 150 mg) + 1.50 mg palonosetron (3 × 0.50 mg).
  4. Percentages are based on N.